Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Q1 2024 Earnings Presentation
12 slides from Moberg Pharma Ab's earnings presentation, May 7, 2024
Slide 1: Interim Report January – March 2024
Interim Report January – March 2024 May 7th, 2024
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis MOB-015 has demonstrated Partnerships in place – potential Launch ongoing under brand name world-leading ability to milestones of USD 70m Terclara® kill nail fungus • 76%1 of patients became fungus • National approvals in 13 EU free, in two phase 3
Slide 4: Significant events during 2024 to date
Significant events during 2024 to date • MOB-015 is launched in Sweden by our partner Allderma under the brand name Terclara® and started to be available on Swedish pharmacy shelves in February. In parallel, work was ongoing in February and March to inform physicians and pharmacists about the unique
Slide 5: Terclara launch in Sweden with partner Allderma
Our partner Allderma AB, a company which specialises in the sale of over- the-counter (OTC) pharmaceuticals – has now launched sales of MOB-015 under the Terclara® brand. • A majority of Swedish pharmacies have the product available on the shelf. • TV marketing started as planned on April 1 • The ph
Slide 6: MOB-015 approval in EU
MOB-015 approval in EU >50% of countries approved as OTC already from start National approval in 13 European countries • The approval in the European Union represents the first marketing authorization for Moberg Pharma´s new onychomycosis treatment worldwide. • Approval supported by two Phase 3 tria
Slide 7: Commercialization rollout of MOB-015
Commercialization rollout of MOB-015 • Two-step process, driven by: 1. Moberg Pharma believe the results in the ongoing North American study is likely to strengthen the product claims further, including a shorter dosing regimen with the potential to deliver superior complete cure rates 2. Need to se
Slide 8: Additional phase 3 study in North America ongoing
Additional phase 3 study in North America ongoing The North American Phase 3 study is progressing according to plan • Similar design as the already completed North American study – Multi-center, double-blind, randomized, vehicle-controlled study – Includes 384 patients in North America, 50% complete
Slide 9: US commercialization ongoing
US commercialization ongoing • US Strategy - utilize the full potential and the knowledge from our first-generation product Kerasal Nail® – Build our own presence in the US market for podiatrists – Collaborate with a company with an established sales force for dermatologists • Collaboration with Bac
Slide 10: Key Financials
Key Financials Last five quarters (SEK thousand) Jan-Mar Oct-Dec Jul-sep Apr-Jun Jan-Mar 2024 2023 2023 2023 2023 Net revenue 820 - - - - Cost of goods sold -328 - - - - Launch of Terclara in Sweden in Gross profit 492 - - - - February. Initial revenue and COGS reported* Selling expenses -1,108 -1,1
Slide 11: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis MOB-015 has demonstrated Partnerships in place – potential Launch ongoing under brand name world-leading ability to milestones of USD 70m Terclara® kill nail fungus • 76%1 of patients became fungus • National approvals in 13 EU free, in two phase 3
Slide 12: Moberg Pharma AB (Publ)
Moberg Pharma AB (Publ) Gustavslundsvägen 42, 5 tr. 167 51 Bromma mobergpharma.se